← Issue №19/ week of Nov 8, 2026/IBD

Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD retrospective · n=450 · Nov 2, 2026 · Inflamm Bowel Dis · IF 4.5

Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy.

New evidence
Clinical takeawayNo clinical action yet: a retrospective cohort study showing IBD patients may have fewer oral irAEs on ICIs, possibly due to the protective effects of concurrent IBD therapies, but no specific management changes are supported.
What it foundIBD patients on ICIs had fewer oral irAEs (specific symptoms and lesion frequency) and less supportive care use compared to non-IBD patients.
ContextAddresses whether IBD predisposes to oral checkpoint-inhibitor toxicity; IBD patients had fewer oral irAEs, and ICI therapy was paused in similar proportions.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Wali S … Wang Y · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues